 |
 |
 |
 |
 |
 |
 |
|
|||||||
|
|
SELECT PUBLICATIONS Ardizzoni A et al; CISCA (CISplatin versus CArboplatin) Meta-analysis Group. Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non small-cell lung cancer: An individual patient data meta-analysis. J Natl Cancer Inst 2007;99(11):847-57. Abstract Arnold AM et al; National Cancer Institute of Canada Clinical Trials Group Study BR.20. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 2007;25(27):4278-84. Abstract Cappuzzo F. Should every lung cancer patient be tested for EGFR mutation? Expert Opin Ther Targets 2006;10(6):789-91. Abstract Clark GM et al; National Cancer Institute of Canada Clinical Trials Group. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer 2006;7(6):389-94. Abstract Gradishar WJ et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23(31):7794-803. Abstract Gridelli C et al. Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: The MILES-2P studies. J Clin Oncol 2007;25(29):4663-9. Abstract Hawkins MJ et al. Study of three weekly nab-paclitaxel regimens in combination with carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC). Proc ASCO 2007;Abstract 7659. Herbst RS et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007;25(30):4743-50. Abstract Heymach JV et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 2007;25(27):4270-7. Abstract Manegold C et al. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. Proc ASCO 2007;Abstract LBA7514. Sandler A et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006a;355(24):2542-50. Abstract Sandler AB et al. Retrospective study of clinical and radiographic risk factors associated with early onset, severe pulmonary hemorrhage in bevacizumab-treated patients with advanced non-small cell lung cancer (NSCLC). Proc ASCO 2006b;Abstract 7068. Sequist LV et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007;25(5):587-95. Abstract Tsao MS et al. Erlotinib in lung cancer — Molecular and clinical predictors of outcome. N Engl J Med 2005;353(2):133-44. Abstract
|
|
